FDA Grants Roche's Giant Cell Arteritis Drug Actemra Breakthrough Status

The U.S. Food and Drug Administration granted breakthrough therapy designation status to Actemra, a giant cell arteritis drug by Roche. Last year, the company also received the designation for their systemic sclerosis research.